- OPTIC trial evaluating response-based dosing regimens of ponatinib in patients with resistant CP-CML met primary endpoint, confirming optimal benefit-risk profile achieved via 45mg/day starting dose ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results